Navigation Links
Nic Vax, A vaccine to put off smoking -No smoke without fire!

Time is ripe for researchers in the United States to begin studies about a vaccine that makes a person immune to the euphoric sensations of smoking//.

Nic vax, the name of the vaccine is undergoing trials, and if this works, it will find itself on the shelves in 2 years time.

The vaccine targets the pleasure inducing sensations owing to nicotine addiction, and impairs them. This results in obliterating the urge to smoke. The vaccine is capable of generating antibodies that will hold on to the nicotine molecules and stop them from getting anywhere close to the brain.

Dr Frank Vocci, director of the US National Institute on Drug Abuse’s division of pharmacotherapies expressed hope that a quick review of the product is expected after which an FDA approval will see the product through in the market. He said “That means they will do a rapid review and get back to the sponsor within so many months. They’ve put a spotlight on it and really tried to move it along, because it would be a unique product.”

The only catch is that the antibodies which a single dose of Nic Vax generates will get depleted in a month. This will necessitate the need for multi-doses. A parallel clinical trial for multi-shot response is being tested on 300 people after which the vaccine will await FDA approval.

A positive stride in smoking cessation initiatives.

'"/>




Page: 1

Related medicine news :

1. New hope for cancer victims – will vaccine cure the deadly bug
2. New vaccine helps allergy and asthma patients
3. Man against HIV – new vaccine ready for human trials
4. New vaccine helps allergy and asthma patients
5. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
6. HIV did not arise from polio vaccine
7. Double impact vaccine
8. High Demand for a child vaccine
9. A new vaccine for leukemia
10. Shortage of MMR vaccine
11. Anthrax vaccine produced
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... 25, 2017 , ... Somnoware, a leading provider of digital ... module. Using this new feature, sleep physicians can now predict the likelihood of ... airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The Somnoware ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the ... CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed tablet in ...
(Date:4/24/2017)... Salt Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... in their efforts to encourage sustainability, innovate new strategies to reduce waste, and support ... all-natural herbal remedy provider. They look to nature to find solutions for health issues, ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, eyewear, ... the rarified air of pop and film stardom.(1) Not to be left out is ... smile. Grins now run the gamut from being encrusted with jewels and precious metals ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: